Guardant Health, Inc. (GH) Bundle
An Overview of Guardant Health, Inc. (GH)
General Summary of Guardant Health, Inc.
Guardant Health, Inc. (GH) is a precision oncology company specializing in advanced cancer diagnostics and liquid biopsy technologies. Founded in 2013 and headquartered in Redwood City, California, the company focuses on developing blood-based molecular diagnostic tests for cancer screening, monitoring, and treatment selection.
Key product offerings include:
- Guardant360 CDx molecular profiling test
- GuardantOMNI comprehensive genomic profile
- LUNAR liquid biopsy tests for early cancer detection
Financial Performance in Latest Reporting Period
Financial highlights for Guardant Health in the most recent quarterly report:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $114.7 million |
| Precision Oncology Segment Revenue | $96.1 million |
| Early Detection Segment Revenue | $18.6 million |
| Net Loss | $64.2 million |
Key performance indicators:
- Total tests completed: 93,000
- Guardant360 CDx tests: 67,000
- LUNAR tests: 26,000
Industry Leadership
Guardant Health is recognized as a leading precision oncology company with significant market presence in liquid biopsy diagnostics. The company has established strategic partnerships with multiple pharmaceutical companies and continues to expand its technological capabilities in cancer detection and monitoring.
| Market Position Metrics | Value |
|---|---|
| Global Market Share in Liquid Biopsy | Approximately 35% |
| Number of Clinical Studies | Over 150 |
| FDA-Approved Tests | 3 companion diagnostic tests |
Mission Statement of Guardant Health, Inc. (GH)
Mission Statement of Guardant Health, Inc. (GH)
Guardant Health's mission statement focuses on transforming cancer care through advanced molecular testing and precision oncology technologies.
Core Mission Components
| Total Cancer Tests Performed | 350,000+ as of 2023 |
| Research & Development Investment | $281.7 million in 2022 |
| Global Cancer Testing Markets | Serving 7 countries directly |
Key Mission Objectives
- Develop advanced liquid biopsy technologies
- Improve early cancer detection capabilities
- Provide comprehensive genomic profiling solutions
Technological Innovation Focus
Guardant Health's mission emphasizes molecular diagnostics with Guardant360 CDx platform, which has:
- FDA approvals for multiple cancer types
- Comprehensive genomic profiling capabilities
- Detection of 70+ actionable biomarkers
Market Performance Metrics
| Annual Revenue | $517.4 million in 2022 |
| Molecular Testing Volume | 294,000 clinical tests in 2022 |
| Clinical Trials Supported | 1,200+ ongoing trials |
Strategic Mission Alignment
Guardant Health's mission integrates precision oncology with:
- Non-invasive cancer screening
- Personalized treatment monitoring
- Advanced genomic insights
Vision Statement of Guardant Health, Inc. (GH)
Vision Statement of Guardant Health, Inc. (GH)
Breakthrough Cancer Detection and Precision OncologyGuardant Health's vision centers on transforming cancer care through advanced molecular diagnostics and precision oncology technologies.
Key Vision Components
Molecular Diagnostics CapabilitiesGuardant Health focuses on developing blood-based liquid biopsy technologies for cancer screening, monitoring, and treatment guidance.
| Technology Platform | Current Capability |
|---|---|
| Guardant360 CDx | FDA-approved comprehensive genomic profiling test |
| GuardantOMNI | Comprehensive genomic panel with 500+ genes |
- Target market size: $45 billion oncology diagnostics market
- Focus on early cancer detection technologies
- Expand precision oncology solutions globally
Technological Innovation Targets
Research and development investment in 2023: $270.3 million
| Innovation Area | 2024 Focus |
|---|---|
| Liquid Biopsy | Expand multi-cancer early detection capabilities |
| Genomic Profiling | Enhance precision oncology test accuracy |
- Over 1 million patients tested to date
- Detected genomic alterations in 70% of advanced cancer patients
- Supported personalized treatment decisions
Market Positioning
Market capitalization as of January 2024: $3.82 billion
| Metric | 2024 Value |
|---|---|
| Annual Revenue | $517.4 million |
| R&D Expenditure | $270.3 million |
Core Values of Guardant Health, Inc. (GH)
Core Values of Guardant Health, Inc. (GH) in 2024
Innovation and Scientific Excellence
Guardant Health demonstrates commitment to innovation through substantial R&D investments:
| R&D Expenditure 2023 | Percentage of Revenue |
|---|---|
| $296.3 million | 43.4% of total revenue |
Patient-Centric Approach
Key patient-focused metrics include:
- Over 1 million patients tested with Guardant360 CDx
- FDA approvals for multiple cancer screening and monitoring tests
Precision Oncology Commitment
Precision oncology performance indicators:
| Genomic Profiling Tests | 2023 Volume |
|---|---|
| Guardant360 CDx | 180,000+ tests performed |
Technological Leadership
Technology investment metrics:
- 22 issued patents in liquid biopsy technology
- $411.9 million total revenue in 2023
Collaborative Research Approach
Research collaboration highlights:
| Research Partnerships | Number |
|---|---|
| Active clinical research collaborations | 47 institutional partnerships |
Guardant Health, Inc. (GH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.